CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.

about

The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.

P2860

Q33702987-CFAC96B6-6D75-4490-9149-6E06563F87A5

P2860

CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.

Item

http://www.wikidata.org/entity/Q36082118

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

CPA-7 influences immune profil ...... by inhibiting activated STAT3.

@ast

CPA-7 influences immune profil ...... by inhibiting activated STAT3.

@en

type

Item

label

CPA-7 influences immune profil ...... by inhibiting activated STAT3.

@ast

CPA-7 influences immune profil ...... by inhibiting activated STAT3.

@en

prefLabel

CPA-7 influences immune profil ...... by inhibiting activated STAT3.

@ast

CPA-7 influences immune profil ...... by inhibiting activated STAT3.

@en

P1476

CPA-7 influences immune profil ...... by inhibiting activated STAT3

@en

P2093

Dianjun Li

http://www.w3.org/2001/XMLSchema#string

Fei Zhan

http://www.w3.org/2001/XMLSchema#string

Guannan Mu

http://www.w3.org/2001/XMLSchema#string

Jiazi Wuyang

http://www.w3.org/2001/XMLSchema#string

Juan Zhao

http://www.w3.org/2001/XMLSchema#string

Meihua Liang

http://www.w3.org/2001/XMLSchema#string

Qi Li

http://www.w3.org/2001/XMLSchema#string

Yanqiao Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer

M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer

Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy

Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.

Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.

Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3

Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors.

Strategies and Approaches of Targeting STAT3 for Cancer Treatment.

STAT proteins as novel targets for cancer drug discovery.

P2888

s12885-016-2488-6

P304

504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-016-2488-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Xiaoyi Huang

P577

2016-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045769599

http://www.w3.org/2001/XMLSchema#string

P698

27435207

http://www.w3.org/2001/XMLSchema#string

P932

4952363

http://www.w3.org/2001/XMLSchema#string

CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.

about

P2860

P2860

CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P6179

P698

P932